Update on diagnostic approaches and therapeutic strategies in systemic mastocytosis

Valent, 2014, The serum tryptase test: an emerging robust biomarker in clinical hematology, Expet Rev Hematol, 7, 683, 10.1586/17474086.2014.955008 Lyons, 2016, Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number, Nat Genet, 48, 1564, 10.1038/ng.3696 Valent, 2019, Why the 20% 1 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome, Int Arch Allergy Immunol, 180, 44, 10.1159/000501079 Sanchez-Munoz, 2011, Evaluation of the WHO criteria for the classification of patients with mastocytosis, Mod Pathol, 24, 1157, 10.1038/modpathol.2011.84 Arock, 2015, KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis, Leukemia, 29, 1223, 10.1038/leu.2015.24 Greiner, 2018, Digital PCR: a sensitive and precise method for KIT D816V quantification in mastocytosis, Clin Chem, 64, 547, 10.1373/clinchem.2017.277897 Kristensen, 2014, Mastocytosis Centre, Odense University Hospital (MastOUH). Sensitive KIT D816V mutation analysis of blood as a diagnostic test in mastocytosis, Am J Hematol, 89, 493, 10.1002/ajh.23672 Greiner, 2020, Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis, Haematologica, 105, 366, 10.3324/haematol.2019.217950 Jawhar, 2017, Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers, Blood, 130, 137, 10.1182/blood-2017-01-764423 Hoermann, 2014, The KIT D816V allele burden predicts survival in patients with mastocytosis and correlates with the WHO type of the disease, Allergy, 69, 810, 10.1111/all.12409 Erben, 2014, The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis, Ann Hematol, 93, 81, 10.1007/s00277-013-1964-1 Garcia-Montero, 2006, KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients, Blood, 108, 2366, 10.1182/blood-2006-04-015545 Schwaab, 2013, Comprehensive mutational profiling in advanced systemic mastocytosis, Blood, 122, 2460, 10.1182/blood-2013-04-496448 Escribano, 2009, Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients, J Allergy Clin Immunol, 124, 514, 10.1016/j.jaci.2009.05.003 Muñoz-Gonzalez, 2019, Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis, Blood, 134, 456, 10.1182/blood.2018886507 Jawhar, 2015, Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event, Leukemia, 29, 1115, 10.1038/leu.2015.4 Jawhar, 2016, Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(1) advanced systemic mastocytosis, Leukemia, 30, 136, 10.1038/leu.2015.284 Pardanani, 2016, ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis, Br J Haematol, 175, 534, 10.1111/bjh.13865 Muñoz-Gonzalez, 2018, Impact of somatic and germline mutations on the outcome of systemic mastocytosis, Blood Adv, 2, 2814, 10.1182/bloodadvances.2018020628 Muñoz-Gonzalez, 2019, Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis, Blood, 134, 456, 10.1182/blood.2018886507 Sperr, 2019, International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study, Lancet Haematol, 6, e638, 10.1016/S2352-3026(19)30166-8 Pardanani, 2018, Mayo alliance prognostic system for mastocytosis: clinical and hybrid clinical-molecular models, Blood Adv, 2, 2964, 10.1182/bloodadvances.2018026245 Jawhar, 2019, MARS: mutation-adjusted risk score for advanced systemic mastocytosis, J Clin Oncol, 37, 2846, 10.1200/JCO.19.00640 Muñoz-González, 2021, Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study, Lancet Haematol, 8, e194, 10.1016/S2352-3026(20)30400-2 Khoury, 2022, The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms, Leukemia, 36, 1703, 10.1038/s41375-022-01613-1 Valent, 2021, Refined diagnostic criteria and classification of mast cell disorders: a consensus proposal, HemaSphere, 5, e646, 10.1097/HS9.0000000000000646 Zanotti, 2022, Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis, Leukemia, 36, 516, 10.1038/s41375-021-01406-y Alvarez-Twose, 2016, Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis, J Allergy Clin Immunol, 137, 168, 10.1016/j.jaci.2015.05.008 Valent, 2016, Updated WHO classification emerging treatment concepts, Blood, 129, 1420, 10.1182/blood-2016-09-731893 Valent, 2007, Standards at standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria, Eur J Clin Invest, 37, 435, 10.1111/j.1365-2362.2007.01807.x Escribano, 2002, Mastocytosis: current conception diagnosis and treatment, Ann Hematol, 81, 677, 10.1007/s00277-002-0575-z Arock, 2010, Pathogenesis, classification and treatment of mastocytosis: state-of-the-art in 2010 and future perspectives, Expet Rev Hematol, 3, 497, 10.1586/ehm.10.42 Kettelhut, 1989, A double-blind, placebo controlled crossover trial of ketotifen versus hydroxyzine in the treatment of pediatric mastocytosis, J Allergy Clin Immunol, 83, 866, 10.1016/0091-6749(89)90097-3 Horan, 1990, Cromlyn sodium in the management of systolic mastocytosis, J Allergy Clin Immunol, 85, 10.1016/0091-6749(90)90067-E Tolar, 2004, Leukotriene-receptor inhibition for the treatment systemic mastocytosis, N Engl J Med, 350, 735, 10.1056/NEJM200402123500723 Butterfield, 2009, Survey of Aspirin administration in systemic mastocytosis, Prostag Other Lipid Mediat, 88, 122, 10.1016/j.prostaglandins.2009.01.001 Bonadonna, 2008, Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy, J Allergy Clin Immunol, 256, 10.1016/j.jaci.2007.10.014 Bonadonna, 2013, Venom immunotherapy in patients with clonal mast cell disorders: efficacy, safety and practical considerations, J Allergy Clin Immunol Pract, 1, 474, 10.1016/j.jaip.2013.06.014 Broesby-Olsen, 2018, Omaluzimab prevents anaphylaxis and improves symptoms in systemic mastocytosis; efficacy and safety observations, Allergy, 73, 230, 10.1111/all.13237 Jendoubi, 2020, Omaluzomab in the treatment of adult patients with mastocytosis: a systematic review, Clin Exp Allergy, 50, 654, 10.1111/cea.13592 Gülsen, 2021, Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis, Allergol Select, 5, 128, 10.5414/ALX02196E Kluin-Nelemans, 2003, Cladrabine therapy for systemic mastocytosis, Blood, 102, 4270, 10.1182/blood-2003-05-1699 Simon, 2004, Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature, Pathol Biol (Paris), 52, 294, 10.1016/j.patbio.2004.04.012 Lim, 2009, Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine, Am J Hematol, 84, 790, 10.1002/ajh.21561 Laroche, 2007, Clinical and densitometric efficacy of the association of interferon alpha and pamidronate in the treatment of osteoporosis in patients with systemic mastocytosis, Clin Rheumatol, 26, 242, 10.1007/s10067-006-0369-0 Barete, 2015, Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis, Blood, 126, 1009, 10.1182/blood-2014-12-614743 Alvarez-Twose, 2012, Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis, J Clin Oncol, 30, e126, 10.1200/JCO.2011.38.9973 Alvarez-Twose, 2016, Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature, Oncotarget, 8, 68950, 10.18632/oncotarget.10711 Gotlib, 2016, Efficacy and safety of midostaurin in advanced systemic mastocytosis, N Engl J Med, 374, 2530, 10.1056/NEJMoa1513098 Reiter, 2017, vol. 102 Gotlib, 2021, Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial, Nat Med, 27, 2192, 10.1038/s41591-021-01539-8 DeAngelo, 2021, Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial, Nat Med, 27, 2183, 10.1038/s41591-021-01538-9 Deininger, 2021, Effective Control of advanced systemic mastocytosis with Avapritinib: mutational analysis from Explorer clinical study, Blood, 138, 318, 10.1182/blood-2021-150872 Reiter, 2022, Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis, Leukemia, 36, 2108, 10.1038/s41375-022-01615-z Gotlib, 2021, A phase 2 study of Bezuclastinib (CGT9486), an oral, selective, and potent KIT D816V inhibitor, in adult patients with advanced systemic mastocytosis (AdvSM), Blood, 138, 3636, 10.1182/blood-2021-145928 Ustun, 2014, Hematopoietic stem-cell transplantation for advanced systemic mastocytosis, J Clin Oncol, 32, 3264, 10.1200/JCO.2014.55.2018 Ustin, 2016, Consensus opinion on allogeneic hematopoietic cell transplantation in advanced systemic mastocytosis, Biol Blood Marrow Transplant, 22, 1348, 10.1016/j.bbmt.2016.04.018 Gotlib, 2019, NCCN clinical practice guidelines in oncology 2018, Oncology, 16 George, 2021, Efficacy of avapritinib in patients with advanced systemic mastocytosis: hematologic and bone marrow responses from the phase 2 open-label, single-arm, pathfinder study, Blood, 2565, 10.1182/blood-2021-146873 Gotlib, 2020, Pure pathologic response is associated with improved overall survival in patients with advanced systemic mastocytosis receiving avapritinib in the phase I EXPLORER study, Blood, 136, 37, 10.1182/blood-2020-137413 Gotlib, 2022, Proposed European competence network on mastocytosis-American initiative in mast cell diseases (ECNM-AIM) response criteria in advanced systemic mastocytosis, J Allergy Clin Immunol Pract, 10, 2025, 10.1016/j.jaip.2022.05.034